Net Loss Per Share

9 Months Ended

Sep. 30, 2023

9. Net Loss Per Share

The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods indicated due to their anti-dilutive effect:


	Nine Months Ended September 30,
	2023		2022
Stock options to purchase common stock		4,679,027		3,123,221
Unvested RSUs		987,550		1,118,735
Warrants to purchase common stock1		10,412,805		13,358,782
Conversion shares under the term loan with K2HV		590,816		—
ESPP		9,758		20,353
Total		16,679,956		17,621,091

1 The table above excludes pre-funded warrants issued in connection with the July 2022 public offering (see Note 7).